Which happens to be in late Phase 2 trials for the treating chronic kidney disease nettapotek.

Abbott, Reata enter agreement to commercialize bardoxolone medication for CKD Abbott and Reata Pharmaceuticals today announced they have entered right into a collaboration agreement to develop and commercialize bardoxolone methyl , which happens to be in late Phase 2 trials for the treating chronic kidney disease .S nettapotek ., excluding certain Asian markets. Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusKidney failing predictors in adolescents: an interview with Dr.D., senior vice president, pharmaceuticals, research and development, Abbott.